JP2017518072A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518072A5 JP2017518072A5 JP2017512424A JP2017512424A JP2017518072A5 JP 2017518072 A5 JP2017518072 A5 JP 2017518072A5 JP 2017512424 A JP2017512424 A JP 2017512424A JP 2017512424 A JP2017512424 A JP 2017512424A JP 2017518072 A5 JP2017518072 A5 JP 2017518072A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- amino acid
- library
- acid residue
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000539 amino acid group Chemical group 0.000 claims 46
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 20
- 239000004471 Glycine Substances 0.000 claims 10
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 10
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 10
- 235000004279 alanine Nutrition 0.000 claims 10
- 210000004899 c-terminal region Anatomy 0.000 claims 10
- 229960000310 isoleucine Drugs 0.000 claims 10
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 10
- 239000004474 valine Substances 0.000 claims 10
- 108060003951 Immunoglobulin Proteins 0.000 claims 9
- 102000018358 immunoglobulin Human genes 0.000 claims 9
- AETVBWZVKDOWHH-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-(1-ethylazetidin-3-yl)oxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OC1CN(C1)CC AETVBWZVKDOWHH-UHFFFAOYSA-N 0.000 claims 7
- 150000007523 nucleic acids Chemical group 0.000 claims 7
- 229940024606 amino acid Drugs 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021087053A JP7454525B2 (ja) | 2014-05-16 | 2021-05-24 | 改善された免疫グロブリン可変ドメイン |
| JP2024037026A JP2024069377A (ja) | 2014-05-16 | 2024-03-11 | 改善された免疫グロブリン可変ドメイン |
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461994552P | 2014-05-16 | 2014-05-16 | |
| US61/994,552 | 2014-05-16 | ||
| US201462014015P | 2014-06-18 | 2014-06-18 | |
| US201461014015P | 2014-06-18 | 2014-06-18 | |
| US62/014,015 | 2014-06-18 | ||
| US201462040167P | 2014-08-21 | 2014-08-21 | |
| US62/040,167 | 2014-08-21 | ||
| US201462047560P | 2014-09-08 | 2014-09-08 | |
| US62/047,560 | 2014-09-08 | ||
| US201562133600P | 2015-03-16 | 2015-03-16 | |
| US62/133,600 | 2015-03-16 | ||
| PCT/EP2015/060643 WO2015173325A2 (en) | 2014-05-16 | 2015-05-13 | Improved immunoglobulin variable domains |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018122878A Division JP7098439B2 (ja) | 2014-05-16 | 2018-06-28 | 改善された免疫グロブリン可変ドメイン |
| JP2021087053A Division JP7454525B2 (ja) | 2014-05-16 | 2021-05-24 | 改善された免疫グロブリン可変ドメイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017518072A JP2017518072A (ja) | 2017-07-06 |
| JP2017518072A5 true JP2017518072A5 (OSRAM) | 2018-06-21 |
| JP7325928B2 JP7325928B2 (ja) | 2023-08-15 |
Family
ID=91193230
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512424A Active JP7325928B2 (ja) | 2014-05-16 | 2015-05-13 | 改善された免疫グロブリン可変ドメイン |
| JP2018122878A Active JP7098439B2 (ja) | 2014-05-16 | 2018-06-28 | 改善された免疫グロブリン可変ドメイン |
| JP2020167247A Active JP7471987B2 (ja) | 2014-05-16 | 2020-10-01 | 改善された免疫グロブリン可変ドメイン |
| JP2021087053A Active JP7454525B2 (ja) | 2014-05-16 | 2021-05-24 | 改善された免疫グロブリン可変ドメイン |
| JP2024004779A Pending JP2024041939A (ja) | 2014-05-16 | 2024-01-16 | 改善された免疫グロブリン可変ドメイン |
| JP2024037026A Pending JP2024069377A (ja) | 2014-05-16 | 2024-03-11 | 改善された免疫グロブリン可変ドメイン |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018122878A Active JP7098439B2 (ja) | 2014-05-16 | 2018-06-28 | 改善された免疫グロブリン可変ドメイン |
| JP2020167247A Active JP7471987B2 (ja) | 2014-05-16 | 2020-10-01 | 改善された免疫グロブリン可変ドメイン |
| JP2021087053A Active JP7454525B2 (ja) | 2014-05-16 | 2021-05-24 | 改善された免疫グロブリン可変ドメイン |
| JP2024004779A Pending JP2024041939A (ja) | 2014-05-16 | 2024-01-16 | 改善された免疫グロブリン可変ドメイン |
| JP2024037026A Pending JP2024069377A (ja) | 2014-05-16 | 2024-03-11 | 改善された免疫グロブリン可変ドメイン |
Country Status (25)
| Country | Link |
|---|---|
| US (10) | US12180268B2 (OSRAM) |
| EP (4) | EP3693386A1 (OSRAM) |
| JP (6) | JP7325928B2 (OSRAM) |
| KR (5) | KR20180091115A (OSRAM) |
| CN (3) | CN113717280A (OSRAM) |
| AU (6) | AU2015261536B2 (OSRAM) |
| BR (2) | BR122018009619B1 (OSRAM) |
| CA (2) | CA2948076A1 (OSRAM) |
| DK (2) | DK3248986T3 (OSRAM) |
| ES (2) | ES2912069T3 (OSRAM) |
| HR (2) | HRP20220400T1 (OSRAM) |
| HU (2) | HUE050007T2 (OSRAM) |
| IL (6) | IL295534B2 (OSRAM) |
| LT (2) | LT3143042T (OSRAM) |
| MX (4) | MX383560B (OSRAM) |
| NZ (1) | NZ726448A (OSRAM) |
| PH (1) | PH12016502282B1 (OSRAM) |
| PL (2) | PL3248986T3 (OSRAM) |
| PT (2) | PT3248986T (OSRAM) |
| RS (2) | RS60717B1 (OSRAM) |
| RU (1) | RU2746738C2 (OSRAM) |
| SG (3) | SG10201810124PA (OSRAM) |
| SI (2) | SI3248986T1 (OSRAM) |
| WO (1) | WO2015173325A2 (OSRAM) |
| ZA (5) | ZA201607587B (OSRAM) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| JP6258199B2 (ja) | 2011-06-23 | 2018-01-10 | アブリンクス エン．ヴェー． | 免疫グロブリン単一可変ドメインを伴うアッセイにおける非特異的タンパク質干渉を予測、検出及び低減するための技術 |
| IL318433A (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable complexes |
| SI3248986T1 (sl) * | 2014-05-16 | 2022-04-29 | Ablynx Nv | Variabilne domene imunoglobulina |
| JP7001474B2 (ja) | 2015-01-21 | 2022-01-19 | インヒブルクス，インコーポレイティド | 非免疫原性単一ドメイン抗体 |
| NO2768984T3 (OSRAM) * | 2015-11-12 | 2018-06-09 | ||
| US10875918B2 (en) | 2015-11-12 | 2020-12-29 | Ablynx N.V. | P2X7 receptor binders and polypeptides comprising the same |
| AU2016351710B2 (en) | 2015-11-13 | 2023-08-03 | Ablynx Nv | Improved serum albumin-binding immunoglobulin variable domains |
| WO2017085172A2 (en) * | 2015-11-18 | 2017-05-26 | Ablynx Nv | Improved serum albumin binders |
| CA3003777A1 (en) | 2015-11-18 | 2017-05-26 | Merck Sharp & Dohme Corp. | Pd1/ctla4 binders |
| MA43260A (fr) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Liants pd1 et/ou lag3 |
| CA3004900C (en) * | 2015-11-18 | 2021-08-10 | Merck Sharp & Dohme Corp. | Ctla4 binders |
| WO2017137579A1 (en) | 2016-02-12 | 2017-08-17 | Ablynx Nv | Method for the production of immunoglobulin single variable domains |
| CN107400166A (zh) * | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
| IL263704B2 (en) | 2016-06-23 | 2024-09-01 | Ablynx Nv | Improved pharmacokinetic assays for immunoglobulin single variable domains |
| EP3541846A1 (en) | 2016-11-16 | 2019-09-25 | Ablynx NV | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
| RU2022101604A (ru) * | 2016-12-07 | 2022-03-29 | Аблинкс Нв | Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином |
| KR102653724B1 (ko) | 2017-01-17 | 2024-04-02 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합제 |
| CN110191896B (zh) | 2017-01-17 | 2023-09-29 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合物 |
| US11261260B2 (en) | 2017-06-02 | 2022-03-01 | Merck Patent Gmbh | ADAMTS binding immunoglobulins |
| CN111108126B (zh) | 2017-07-19 | 2024-04-26 | 非营利性组织佛兰芒综合大学生物技术研究所 | 血清白蛋白结合剂 |
| KR20200091400A (ko) | 2017-10-31 | 2020-07-30 | 브이아이비 브이지더블유 | 신규한 항원-결합 키메라 단백질 및 이의 방법 및 용도 |
| WO2020176478A1 (en) | 2019-02-25 | 2020-09-03 | The University Of Chicago | Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents |
| WO2020221888A1 (en) | 2019-04-30 | 2020-11-05 | Vib Vzw | Cystic fibrosis transmembrane conductance regulator stabilizing agents |
| EP4065603A1 (en) | 2019-11-27 | 2022-10-05 | Vib Vzw | Positive allosteric modulators of the calcium-sensing receptor |
| AU2020397210A1 (en) | 2019-12-06 | 2022-07-28 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting TNFa and OX40L |
| CA3163877A1 (en) * | 2019-12-06 | 2021-06-10 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting tnf.alpha. and il-23 |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| TW202530257A (zh) | 2019-12-09 | 2025-08-01 | 比利時商艾伯霖克斯公司 | 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽 |
| US20240027467A1 (en) | 2019-12-20 | 2024-01-25 | Vib Vzw | Nanobody Exchange Chromatography |
| WO2021156490A2 (en) | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
| IL295892A (en) | 2020-02-25 | 2022-10-01 | Vib Vzw | Leucine-rich repeat kinase 2 allosteric modulators |
| MX2022012278A (es) | 2020-03-30 | 2022-10-27 | Ablynx Nv | Metodo para la produccion y purificacion de dominios variables unicos de inmunoglobulina multivalentes. |
| WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
| US20230272094A1 (en) * | 2020-08-05 | 2023-08-31 | Synthekine, Inc. | Il2rb/il2rg synthetic cytokines |
| MX2023003522A (es) | 2020-09-25 | 2023-04-19 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l. |
| US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| PH12023500013A1 (en) | 2020-12-04 | 2024-03-11 | Tidal Therapeutics Inc | Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof |
| US20240092919A1 (en) | 2020-12-18 | 2024-03-21 | Ablynx N. V. | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| IL303783A (en) | 2020-12-18 | 2023-08-01 | Sanofi Sa | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| US11897951B2 (en) | 2020-12-18 | 2024-02-13 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α |
| GB202020502D0 (en) | 2020-12-23 | 2021-02-03 | Vib Vzw | Antibody composistion for treatment of corona virus infection |
| AU2022216460A1 (en) | 2021-02-05 | 2023-09-21 | Universiteit Gent | Sarbecovirus binders |
| CN117794566A (zh) | 2021-02-05 | 2024-03-29 | Vib研究所 | 沙贝病毒结合剂 |
| CA3211270A1 (en) | 2021-02-19 | 2022-08-25 | Vib Vzw | Cation-independent mannose-6-phosphate receptor binders |
| CN117043184A (zh) * | 2021-04-01 | 2023-11-10 | 南京再明医药有限公司 | 抗人血清白蛋白（hsa）的纳米抗体及其应用 |
| CA3228014A1 (en) | 2021-07-30 | 2023-02-16 | Vib Vzm | Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation |
| JP2024543134A (ja) * | 2021-11-29 | 2024-11-19 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 修飾されたタンパク質又はポリペプチド |
| MX2024007564A (es) | 2021-12-17 | 2024-07-04 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tcr\03b1\03b2, cd33 y cd123. |
| CA3248241A1 (en) | 2022-01-12 | 2023-07-20 | Vib Vzw | HUMAN NTCP BINDERS FOR THERAPEUTIC USE AND TARGETED LIVER ADMINISTRATION |
| WO2023198848A1 (en) | 2022-04-13 | 2023-10-19 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| EP4273162A1 (en) * | 2022-05-06 | 2023-11-08 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
| EP4519309A1 (en) | 2022-05-06 | 2025-03-12 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
| US20250313611A1 (en) | 2022-05-18 | 2025-10-09 | Vib Vzw | Sarbecovirus spike s2 subunit binders |
| IL317461A (en) | 2022-06-08 | 2025-02-01 | Tidal Therapeutics Inc | Ionized Cationic Lipids and Lipid Nanoparticles and Methods of Synthesis and Use thereof |
| AR129614A1 (es) | 2022-06-14 | 2024-09-11 | Ablynx Nv | Dominios variables únicos de inmunoglobulina que se dirigen al receptor de células t |
| MA71603A (fr) | 2022-07-27 | 2025-05-30 | Ablynx Nv | Polypeptides se liant à un épitope spécifique du récepteur fc néonatal |
| WO2024068744A1 (en) | 2022-09-27 | 2024-04-04 | Vib Vzw | Antivirals against human parainfluenza virus |
| WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| WO2024137731A2 (en) | 2022-12-21 | 2024-06-27 | Genzyme Corporation | Anti‑pd‑1×4‑1bb binding proteins |
| WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
| KR20250133750A (ko) | 2023-01-09 | 2025-09-08 | 오디세이 테라퓨틱스, 인코포레이티드 | 항-tnfr2 항원-결합 단백질 및 그의 용도 |
| IL322564A (en) | 2023-02-10 | 2025-10-01 | Amunix Pharmaceuticals Inc | Prostate-specific membrane antigen (PSMA)-targeting compositions and methods for their preparation and use |
| WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
| WO2024175787A1 (en) | 2023-02-24 | 2024-08-29 | Vrije Universiteit Brussel | Anti-inflammatory pannexin 1 channel inhibitors |
| AU2024234615A1 (en) | 2023-03-14 | 2025-08-21 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| WO2024208816A1 (en) | 2023-04-03 | 2024-10-10 | Vib Vzw | Blood-brain barrier crossing antibodies |
| WO2024231447A1 (en) | 2023-05-08 | 2024-11-14 | Sanofi | Glycosylation of immunoglobulin single variable domains |
| AR132699A1 (es) | 2023-05-17 | 2025-07-23 | Odyssey Therapeutics Inc | Anticuerpos de dominio único modificados |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| AU2024308381A1 (en) | 2023-06-29 | 2025-11-20 | Odyssey Therapeutics, Inc. | Anti-trailr2 antigen-binding proteins and uses thereof |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| AR133903A1 (es) | 2023-09-22 | 2025-11-12 | Ablynx Nv | Agentes de unión de albúmina bi- y multivalentes |
| TW202530265A (zh) | 2023-10-13 | 2025-08-01 | 美商奧迪希治療公司 | 抗cdh17抗原結合蛋白及其用途 |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
| WO2025109176A1 (en) | 2023-11-22 | 2025-05-30 | Exevir Bio Bv | Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same |
| WO2025114529A1 (en) | 2023-12-01 | 2025-06-05 | Ablynx Nv | Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety |
| WO2025125577A1 (en) | 2023-12-14 | 2025-06-19 | Vib Vzw | Antibodies against influenza b virus |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| WO2025133166A1 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based carriers for site-specific amine conjugation |
| WO2025174825A2 (en) | 2024-02-12 | 2025-08-21 | Aera Therapeutics, Inc. | Delivery compositions |
| WO2025181155A1 (en) | 2024-02-26 | 2025-09-04 | Vib Vzw | Human beta-glucocerebrosidase binders and uses thereof |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| US12459994B2 (en) | 2024-04-12 | 2025-11-04 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
| WO2025219231A1 (en) | 2024-04-15 | 2025-10-23 | Vib Vzw | Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope |
| WO2025255558A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof |
| WO2025255435A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Antigen-binding proteins against serum albumin and uses thereof |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1545106C3 (de) * | 1963-07-16 | 1979-05-31 | Union Carbide Corp., New York, N.Y. (V.St.A.) | Verfahren zur Herstellung von linearen Polyarylenpolyäthern |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5028608A (en) | 1989-12-11 | 1991-07-02 | The Trustees Of Princeton University | N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives |
| US5248775A (en) | 1989-12-11 | 1993-09-28 | The Trustees Of Princeton University | Pyrrolo(2,3-d)pyrimidines |
| KR0162654B1 (ko) | 1989-12-11 | 1998-11-16 | 알렌 제이. 시니스갤리 | N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체 |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| ATE452975T1 (de) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| WO1999042077A2 (en) | 1998-02-19 | 1999-08-26 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| EP1328626B1 (en) * | 2000-05-26 | 2013-04-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| EP1412390A2 (en) | 2001-07-26 | 2004-04-28 | Tanox, Inc. | Agents that activate or inhibit toll-like receptor 9 |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| EP2135879A3 (en) | 2002-06-28 | 2010-06-23 | Domantis Limited | Ligand |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
| NZ540196A (en) | 2002-11-08 | 2008-09-26 | Ablynx Nv | Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders |
| EP1558646A2 (en) | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses thereof |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| US9028816B2 (en) | 2003-01-10 | 2015-05-12 | Ablynx N.V. | Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor |
| US7276585B2 (en) * | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| EA012622B1 (ru) | 2004-06-01 | 2009-10-30 | Домэнтис Лимитед | Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки |
| BRPI0518151A2 (pt) | 2004-10-13 | 2009-06-16 | Ablynx Nv | polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo |
| KR20070094909A (ko) | 2004-12-02 | 2007-09-27 | 도만티스 리미티드 | 혈청 알부민 및 ｇｌｐ-1 또는 ｐｙｙ를 표적으로 삼는이중특이성 도메인을 갖는 항체 |
| US20090191217A1 (en) | 2004-12-02 | 2009-07-30 | De Wildt Ruud M | Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses |
| US8188223B2 (en) * | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| ES2694247T3 (es) | 2005-05-20 | 2018-12-19 | Ablynx N.V. | NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación |
| WO2006129843A2 (en) | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Bispecific capturing molecule |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| JP2009519011A (ja) | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット |
| CA2629850A1 (en) | 2005-12-01 | 2007-06-07 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| EP1976991A1 (en) | 2006-01-24 | 2008-10-08 | Domantis Limited | Fusion proteins that contain natural junctions |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| EP2097449A1 (en) | 2006-12-05 | 2009-09-09 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| US8907065B2 (en) | 2006-12-15 | 2014-12-09 | Ablynx N.V. | Polypeptides that modulate the interaction between cells of the immune system |
| WO2009138519A1 (en) | 2008-05-16 | 2009-11-19 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| CN101796072B (zh) | 2007-05-24 | 2014-09-24 | 埃博灵克斯股份有限公司 | 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽 |
| CA2689941C (en) | 2007-06-25 | 2019-10-29 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| EP2215125A1 (en) | 2007-11-27 | 2010-08-11 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| EP2259802A1 (en) | 2008-03-31 | 2010-12-15 | Glaxo Group Limited | Drug fusions and conjugates |
| JP2011516603A (ja) | 2008-04-17 | 2011-05-26 | アブリンクス エン．ヴェー． | 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド |
| WO2009138494A2 (en) * | 2008-05-15 | 2009-11-19 | Ablynx N.V. | Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| EP2143735A1 (en) * | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US20110200525A1 (en) | 2008-10-09 | 2011-08-18 | Patz Jr Edward F | Vhh antibody fragments for use in the detection and treatment of cancer |
| WO2010108937A2 (en) | 2009-03-27 | 2010-09-30 | Glaxo Group Limited | Drug fusions and conjugates |
| PT2424889E (pt) | 2009-04-30 | 2015-11-12 | Ablynx Nv | Método de produção de anticorpos de domínio |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| EP2435480A1 (en) | 2009-05-27 | 2012-04-04 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
| CN102458471A (zh) | 2009-05-28 | 2012-05-16 | 葛兰素集团有限公司 | 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合 |
| US9150640B2 (en) | 2009-07-10 | 2015-10-06 | Ablynx N.V. | Method for the production of variable domains |
| US8306355B2 (en) | 2009-07-13 | 2012-11-06 | Sharp Laboratories Of America, Inc. | Methods and systems for reducing compression artifacts |
| US20110117113A1 (en) | 2009-10-09 | 2011-05-19 | Gerald Beste | Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them |
| US8962807B2 (en) * | 2009-12-14 | 2015-02-24 | Ablynx N.V. | Single variable domain antibodies against OX40L, constructs and therapeutic use |
| EP4219545A1 (en) * | 2009-12-23 | 2023-08-02 | Novartis AG | Method for decreasing immunogenicity |
| EA201201227A1 (ru) | 2010-03-03 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Бипаратопные а-бета-связывающие полипептиды |
| EP2552962B1 (en) | 2010-03-26 | 2016-03-23 | Ablynx N.V. | Immunoglobulin single variable domains directed against cxcr7 |
| CA2800292A1 (en) | 2010-04-30 | 2011-11-03 | Ablynx Nv | Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine il-23 |
| EP2571901B1 (en) | 2010-05-20 | 2019-01-02 | Ablynx N.V. | Biological materials related to her3 |
| WO2011161266A1 (en) | 2010-06-25 | 2011-12-29 | Ablynx Nv | Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4 |
| JP2013145769A (ja) | 2010-08-04 | 2013-07-25 | Kri Inc | 異方性希土類ボンド磁石とその製造方法 |
| WO2012042026A1 (en) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
| US20130310281A1 (en) * | 2011-02-02 | 2013-11-21 | Glaxo Group Limited | Novel antigen binding proteins |
| US20150158948A9 (en) | 2011-03-28 | 2015-06-11 | Francis Descamps | Bispecific anti-cxcr7 immunoglobulin single variable domains |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| HRP20192160T1 (hr) * | 2011-06-23 | 2020-02-21 | Ablynx N.V. | Vezujući proteini serumskog albumina |
| IN2014CN00437A (OSRAM) | 2011-06-23 | 2015-04-03 | Ablynx Nv | |
| JP6258199B2 (ja) | 2011-06-23 | 2018-01-10 | アブリンクス エン．ヴェー． | 免疫グロブリン単一可変ドメインを伴うアッセイにおける非特異的タンパク質干渉を予測、検出及び低減するための技術 |
| US20130019175A1 (en) | 2011-07-14 | 2013-01-17 | Microsoft Corporation | Submenus for context based menu system |
| UA118833C2 (uk) * | 2011-08-17 | 2019-03-25 | Ґлаксо Ґруп Лімітед | Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1 |
| CN103889451B (zh) | 2011-09-30 | 2016-06-29 | 埃博灵克斯股份有限公司 | 与C-Met相关的生物物质 |
| MY172946A (en) | 2011-10-17 | 2019-12-16 | Regeneron Pharma | Restricted immunoglobulin heavy chain mice |
| US20130129727A1 (en) | 2011-11-17 | 2013-05-23 | Nanjingjinsirui Science & Technology Biology Corporation | Methods and systems for increasing protein stability |
| HUE056335T2 (hu) * | 2012-01-31 | 2022-02-28 | Regeneron Pharma | ASIC1-ellenes antitestek és alkalmazásaik |
| CN104507964B (zh) | 2012-06-01 | 2020-05-15 | 埃博灵克斯股份有限公司 | P2x7受体拮抗剂和激动剂 |
| TWI641619B (zh) * | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| US20140161796A1 (en) * | 2012-09-13 | 2014-06-12 | Andreas Loew | Single chain proteins with c-terminal modifications |
| US9667316B2 (en) | 2013-05-17 | 2017-05-30 | The Boeing Company | Aircraft data transmission using phase separation |
| SI3248986T1 (sl) * | 2014-05-16 | 2022-04-29 | Ablynx Nv | Variabilne domene imunoglobulina |
| JP6936797B2 (ja) | 2015-10-30 | 2021-09-22 | アブリンクス エン．ヴェー． | Ｉｌ−２３に対するポリペプチド |
| NO2768984T3 (OSRAM) | 2015-11-12 | 2018-06-09 | ||
| US10875918B2 (en) | 2015-11-12 | 2020-12-29 | Ablynx N.V. | P2X7 receptor binders and polypeptides comprising the same |
| AU2016351710B2 (en) | 2015-11-13 | 2023-08-03 | Ablynx Nv | Improved serum albumin-binding immunoglobulin variable domains |
| WO2017085172A2 (en) | 2015-11-18 | 2017-05-26 | Ablynx Nv | Improved serum albumin binders |
| MA43260A (fr) | 2015-11-18 | 2018-09-26 | Merck Sharp & Dohme | Liants pd1 et/ou lag3 |
| CA3004900C (en) | 2015-11-18 | 2021-08-10 | Merck Sharp & Dohme Corp. | Ctla4 binders |
| CA3003777A1 (en) | 2015-11-18 | 2017-05-26 | Merck Sharp & Dohme Corp. | Pd1/ctla4 binders |
| KR102653724B1 (ko) | 2017-01-17 | 2024-04-02 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합제 |
| CA3163877A1 (en) | 2019-12-06 | 2021-06-10 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting tnf.alpha. and il-23 |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| US11897951B2 (en) | 2020-12-18 | 2024-02-13 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α |
-
2015
- 2015-05-13 SI SI201531807T patent/SI3248986T1/sl unknown
- 2015-05-13 SI SI201531267T patent/SI3143042T1/sl unknown
- 2015-05-13 AU AU2015261536A patent/AU2015261536B2/en active Active
- 2015-05-13 CA CA2948076A patent/CA2948076A1/en active Pending
- 2015-05-13 PT PT171789902T patent/PT3248986T/pt unknown
- 2015-05-13 RS RS20201034A patent/RS60717B1/sr unknown
- 2015-05-13 SG SG10201810124PA patent/SG10201810124PA/en unknown
- 2015-05-13 BR BR122018009619-5A patent/BR122018009619B1/pt active IP Right Grant
- 2015-05-13 EP EP20163286.6A patent/EP3693386A1/en active Pending
- 2015-05-13 JP JP2017512424A patent/JP7325928B2/ja active Active
- 2015-05-13 PL PL17178990T patent/PL3248986T3/pl unknown
- 2015-05-13 PH PH1/2016/502282A patent/PH12016502282B1/en unknown
- 2015-05-13 RU RU2016149463A patent/RU2746738C2/ru active
- 2015-05-13 IL IL295534A patent/IL295534B2/en unknown
- 2015-05-13 EP EP20167969.3A patent/EP3702369A1/en active Pending
- 2015-05-13 BR BR112016026773A patent/BR112016026773A2/pt not_active Application Discontinuation
- 2015-05-13 EP EP15722211.8A patent/EP3143042B1/en active Active
- 2015-05-13 DK DK17178990.2T patent/DK3248986T3/da active
- 2015-05-13 ES ES17178990T patent/ES2912069T3/es active Active
- 2015-05-13 KR KR1020187022490A patent/KR20180091115A/ko not_active Ceased
- 2015-05-13 HR HRP20220400TT patent/HRP20220400T1/hr unknown
- 2015-05-13 KR KR1020237012548A patent/KR102827683B1/ko active Active
- 2015-05-13 US US15/311,564 patent/US12180268B2/en active Active
- 2015-05-13 RS RS20220328A patent/RS63085B1/sr unknown
- 2015-05-13 CA CA3175002A patent/CA3175002A1/en active Pending
- 2015-05-13 SG SG10201805288QA patent/SG10201805288QA/en unknown
- 2015-05-13 LT LTEP15722211.8T patent/LT3143042T/lt unknown
- 2015-05-13 EP EP17178990.2A patent/EP3248986B1/en active Active
- 2015-05-13 MX MX2016014926A patent/MX383560B/es unknown
- 2015-05-13 IL IL299282A patent/IL299282B2/en unknown
- 2015-05-13 WO PCT/EP2015/060643 patent/WO2015173325A2/en not_active Ceased
- 2015-05-13 ES ES15722211T patent/ES2815572T3/es active Active
- 2015-05-13 KR KR1020237012493A patent/KR102769509B1/ko active Active
- 2015-05-13 CN CN202111040888.8A patent/CN113717280A/zh active Pending
- 2015-05-13 LT LTEP17178990.2T patent/LT3248986T/lt unknown
- 2015-05-13 CN CN201810899732.7A patent/CN109053885A/zh active Pending
- 2015-05-13 PT PT157222118T patent/PT3143042T/pt unknown
- 2015-05-13 HU HUE15722211A patent/HUE050007T2/hu unknown
- 2015-05-13 IL IL311293A patent/IL311293B2/en unknown
- 2015-05-13 HR HRP20200966TT patent/HRP20200966T1/hr unknown
- 2015-05-13 KR KR1020167035012A patent/KR20170002645A/ko not_active Ceased
- 2015-05-13 KR KR1020237033317A patent/KR20230145503A/ko active Pending
- 2015-05-13 CN CN201580037310.3A patent/CN106661100A/zh active Pending
- 2015-05-13 HU HUE17178990A patent/HUE058008T2/hu unknown
- 2015-05-13 DK DK15722211.8T patent/DK3143042T3/da active
- 2015-05-13 NZ NZ726448A patent/NZ726448A/en unknown
- 2015-05-13 PL PL15722211T patent/PL3143042T3/pl unknown
- 2015-05-13 SG SG11201609162SA patent/SG11201609162SA/en unknown
-
2016
- 2016-10-31 IL IL248636A patent/IL248636B2/en unknown
- 2016-11-03 ZA ZA2016/07587A patent/ZA201607587B/en unknown
- 2016-11-14 MX MX2021007020A patent/MX2021007020A/es unknown
- 2016-11-14 MX MX2018007581A patent/MX2018007581A/es unknown
- 2016-11-14 MX MX2023010731A patent/MX2023010731A/es unknown
-
2018
- 2018-06-12 IL IL259972A patent/IL259972B/en active IP Right Grant
- 2018-06-14 AU AU2018204226A patent/AU2018204226A1/en not_active Abandoned
- 2018-06-28 JP JP2018122878A patent/JP7098439B2/ja active Active
-
2019
- 2019-11-26 US US16/695,420 patent/US11312764B2/en active Active
-
2020
- 2020-04-16 AU AU2020202570A patent/AU2020202570B2/en active Active
- 2020-04-30 AU AU2020202855A patent/AU2020202855B2/en active Active
- 2020-07-31 ZA ZA2020/04758A patent/ZA202004758B/en unknown
- 2020-07-31 ZA ZA2020/04757A patent/ZA202004757B/en unknown
- 2020-07-31 ZA ZA2020/04759A patent/ZA202004759B/en unknown
- 2020-10-01 JP JP2020167247A patent/JP7471987B2/ja active Active
- 2020-12-09 US US17/116,047 patent/US11220539B2/en active Active
-
2021
- 2021-02-03 ZA ZA2021/00742A patent/ZA202100742B/en unknown
- 2021-03-24 IL IL281755A patent/IL281755B2/en unknown
- 2021-03-29 US US17/215,121 patent/US11485777B2/en active Active
- 2021-03-29 US US17/215,039 patent/US11312765B2/en active Active
- 2021-03-29 US US17/215,163 patent/US11319364B2/en not_active Ceased
- 2021-05-24 JP JP2021087053A patent/JP7454525B2/ja active Active
- 2021-12-27 US US17/562,499 patent/US11485778B2/en active Active
-
2022
- 2022-03-17 US US17/697,508 patent/US20220332806A1/en active Pending
- 2022-03-25 US US17/704,063 patent/US20220332807A1/en active Pending
- 2022-04-13 US US17/719,496 patent/US11708404B2/en active Active
- 2022-11-28 AU AU2022279374A patent/AU2022279374A1/en active Pending
- 2022-11-28 AU AU2022279373A patent/AU2022279373A1/en active Pending
-
2024
- 2024-01-16 JP JP2024004779A patent/JP2024041939A/ja active Pending
- 2024-03-11 JP JP2024037026A patent/JP2024069377A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518072A5 (OSRAM) | ||
| RU2016149463A (ru) | Улучшенные вариабельные домены иммуноглобулина | |
| WO2015138907A3 (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| HRP20220531T1 (hr) | Varijabilni fragmenti antitijela koji se umeću i modificirane a1-a2 domene nkg2d liganda | |
| WO2014177459A3 (en) | Fc-receptor binding modified asymmetric antibodies and methods of use | |
| MX389710B (es) | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos. | |
| JP2016026149A5 (OSRAM) | ||
| MX2023003630A (es) | Aglutinantes de albumina de suero mejorados. | |
| WO2011063003A3 (en) | Peptides and methods for the detection of lyme disease antibodies | |
| WO2018050902A3 (en) | Multimers, tetramers & octamers | |
| WO2017085172A3 (en) | Improved serum albumin binders | |
| EP4296673A3 (en) | Peptides and methods for the detection of lyme disease antibodies | |
| WO2016018740A3 (en) | Purification platform for bispecific antibodies | |
| JP2014193892A5 (OSRAM) | ||
| WO2018134235A8 (en) | Improved serum albumin binders | |
| EP4275698A3 (en) | Anti-tigit antibodies and methods of use thereof | |
| EA201792226A1 (ru) | Полипептиды, содержащие de novo связывающий домен, и их применение | |
| JP2017048194A5 (OSRAM) | ||
| BR112019008702A2 (pt) | polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição. | |
| EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
| WO2017172260A8 (en) | Binding proteins and methods of use thereof | |
| JP2014224126A5 (OSRAM) | ||
| EP4491268A3 (en) | Fc binding proteins with cysteine in the c-terminal helical region | |
| PE20181956A1 (es) | Polipeptidos que inhiben cd40l | |
| JP2016508503A5 (OSRAM) |